← Back to headlines
Analysts Maintain Bullish Stance on Gossamer Bio (GOSS) Despite Phase 3 Setback
Despite a setback in its Phase 3 trials, analysts continue to hold a bullish outlook on Gossamer Bio, indicating long-term confidence in the company.
12 Apr, 21:47 — 12 Apr, 21:47
Sources
Showing 1 of 1 sources
